The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in ...

The researchers found that the primary composite reactogenicity outcome was noninferior in the simultaneous vs the sequential group. (HealthDay News) — Reactogenicity is comparable for simultaneous ...

(HealthDay News) — The supply of health care professionals available to provide HIV care is expected to continue to decline over the next 5 years, according to research published in the ...

NT-501 is an investigational ocular implant that utilizes an encapsulated cell-based delivery system to deliver continuous ciliary neurotrophic factor.

The researchers projected that more than 42,000 deaths could be averted annually, including more than 11,000 among those with type 2 diabetes, with expanded access. (HealthDay News) — Expanding access ...

The FDA has issued a proposal to remove a common decongestant in over the counter products.

Increased relative risk for adverse events seen among those admitted during weeks with high versus low COVID-19 burden ...

Researchers projected that 35.3 million cancer cases are expected worldwide by 2050, representing a 76.6% increase from the 2022 estimate of 20 million. HealthDay News — Cancer disparities are evident ...

Full results from the trial will be presented at an upcoming medical meeting. Topline results from a phase 3 trial show that tezepelumab statistically significantly reduced the size of nasal polyps ...

The Orphan Drug designation was supported by preclinical research and preliminary data from the dose escalation/expansion phase 1/2 trial.

Medication abortion before confirmed intrauterine pregnancy is noninferior to standard, delayed treatment for complete abortion.

HealthDay News — The prevalence of diabetes was 15.8% among US adults during August 2021 to August 2023, according to a November data brief published by the National Center for Health Statistics.